STOCK TITAN

Ocular Therapeutix (OCUL) director receives new RSU and stock option awards

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Ocular Therapeutix director Leslie J. Williams received new equity awards. On June 10, 2026, Williams was granted 14,000 shares of common stock as restricted stock units under the company’s 2021 Stock Incentive Plan. These RSUs vest in full after one year of continued board service or just before the next annual stockholder meeting.

Williams was also granted options to buy 44,000 shares of common stock at an exercise price of $8.74 per share, expiring on June 9, 2036, with the same one-year vesting schedule tied to continued board service. After these grants, Williams directly holds 65,433 shares of common stock and 44,000 stock options.

Positive

  • None.

Negative

  • None.
Insider Williams Leslie J.
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 44,000 $0.00 --
Grant/Award Common Stock 14,000 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 44,000 shares (Direct, null); Common Stock — 65,433 shares (Direct, null)
Footnotes (1)
  1. On June 10, 2026, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Company"). Each RSU represents a right to receive one share of the Company's common stock. Subject to the reporting person's continued service on the Company's board of directors, the RSUs will vest with respect to 100% of the shares underlying the RSUs on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date. Subject to the reporting person's continued service on the Company's board of directors, the options will vest with respect to 100% of the shares underlying the options on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date.
RSU grant 14,000 shares Restricted stock units granted June 10, 2026
Option grant size 44,000 options Stock options granted June 10, 2026
Option exercise price $8.74 per share Strike price for 44,000 stock options
Option expiration June 9, 2036 Expiration date of stock options
Common shares after grant 65,433 shares Direct common stock holdings post-transaction
Options after grant 44,000 options Total stock options held after grant
restricted stock units financial
"the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
2021 Stock Incentive Plan financial
"RSUs under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc."
Stock Option (Right to Buy) financial
"security_title": "Stock Option (Right to Buy)""
vest financial
"the RSUs will vest with respect to 100% of the shares underlying the RSUs on the first anniversary"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
exercise price financial
"conversion_or_exercise_price": "8.7400""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Williams Leslie J.

(Last)(First)(Middle)
C/O OCULAR THERAPEUTIX, INC.
14 CROSBY DRIVE, 3RD FLOOR

(Street)
BEDFORD MASSACHUSETTS 01730

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
OCULAR THERAPEUTIX, INC [ OCUL ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/10/2026A14,000(1)A$065,433D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$8.7406/10/2026A44,000 (2)06/09/2036Common Stock44,000$044,000D
Explanation of Responses:
1. On June 10, 2026, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Company"). Each RSU represents a right to receive one share of the Company's common stock. Subject to the reporting person's continued service on the Company's board of directors, the RSUs will vest with respect to 100% of the shares underlying the RSUs on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date.
2. Subject to the reporting person's continued service on the Company's board of directors, the options will vest with respect to 100% of the shares underlying the options on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date.
/s/ Todd Anderman, Attorney-in-Fact for Leslie J. Williams06/12/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Ocular Therapeutix (OCUL) report for Leslie J. Williams?

Ocular Therapeutix reported that director Leslie J. Williams received equity awards, including restricted stock units and stock options, on June 10, 2026. These awards are part of her board compensation and are subject to time-based vesting tied to continued service.

How many Ocular Therapeutix (OCUL) shares did Leslie J. Williams receive in stock grants?

Leslie J. Williams received 14,000 shares of common stock through restricted stock units. Each RSU converts into one share upon vesting, giving her additional direct ownership if she remains on the board through the specified vesting date.

What stock options were granted to Leslie J. Williams by Ocular Therapeutix (OCUL)?

Williams was granted options to buy 44,000 shares of Ocular Therapeutix common stock at an exercise price of $8.74 per share. These options vest in full after one year of continued board service or immediately before the next annual stockholder meeting.

When do Leslie J. Williams’s new Ocular Therapeutix (OCUL) equity awards vest?

Both the restricted stock units and the stock options vest 100% on the first anniversary of the June 10, 2026 grant date. Vesting can also occur earlier, immediately prior to the next annual meeting of stockholders, if that meeting happens before the anniversary.

What are Leslie J. Williams’s Ocular Therapeutix (OCUL) holdings after these transactions?

Following the June 10, 2026 awards, Leslie J. Williams directly holds 65,433 shares of Ocular Therapeutix common stock. She also holds 44,000 stock options, each giving the right to purchase one share at an exercise price of $8.74 before June 9, 2036.